PTC Therapeutics, Inc. (PTCT)

Over the past six months, PTC Therapeutics' stock has experienced significant activity, increasing by 7.73% in the past month and 80.45% over the last 12 months, trading at $64.49 as of May 8, 2026. Key events include strong Q1 2026 financial results with raised guidance driven by Sephience, positive clinical data from the PIVOT-HD extension study of votoplam for Huntington's disease, and generic erosion of Emflaza. Q1 2025 saw exceptionally high revenue and net income, skewing trailing twelve-month profitability.

There is no explicit information indicating significant demand seasonality for PTC Therapeutics' products and services. The company has reported a consistent and growing demand for Sephience.

PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders, leveraging its expertise in RNA biology, gene therapy, and global commercial infrastructure. The company operates within the Biotechnology and Pharmaceuticals sectors, focusing on rare diseases in neurology and metabolism. Key products include Sephience for PKU, Translarna and Emflaza for DMD, Evrysdi for SMA (royalty revenue via Roche collaboration), Votoplam for Huntington's disease (licensed from Novartis), and Kebilidi for AADC deficiency.

PTC Therapeutics has a global commercial presence with headquarters in Warren, New Jersey, and an international headquarters in Dublin, Ireland. Sephience has launched in the U.S., Europe, Japan, and Brazil, with commercial patients expected in up to 30 countries by the end of 2026. PTC also holds commercialization rights for WAYLIVRA in Latin America.

PTC Therapeutics has experienced a positive shift in its brand reputation in the past year. PatientView's annual survey indicated that PTC Therapeutics was one of only three U.S. companies that significantly improved in patient groups' perceptions.

PTC Therapeutics' ownership is primarily concentrated among institutional investors, with 357 institutional owners holding 91,392,952 shares as of May 1, 2026. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Rtw Investments, Lp. Individual insider holdings accounted for 1.55% of the company's shares in February 2025, with Michael Schmertzler being the largest individual shareholder.